Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Ferguson

Nurse Practitioner, Family Pella, IA Nurse Practitioner

NPI 1558698753 CMS profile 10459865

2605 Washington St, Pella, IA 50219

Open in the dashboard

General payments

$82,020

465 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Ferguson of Pella, IA is reported in the CMS Open Payments database as having received $82,020 across 465 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,109 150
2024 General $20,420 95
2023 General $19,058 134
2022 General $1,318 45
2021 General $2,115 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Ferguson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Megan Ferguson were reported at $39,109. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Megan Ferguson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,115 $124 $35–$379 $132
2022 $1,318 $141 $44–$430 $149
2023 $19,058 $154 $49–$476 $160
2024 $20,420 $165 $51–$504 $164
2025 $39,109 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $73,477 131 payments
  2. AbbVie, Inc. $1,430 62 payments
  3. Janssen Biotech, Inc. $1,183 45 payments
  4. Genzyme Corporation $924 31 payments
  5. Sun Pharmaceutical Industries Inc. $730 27 payments
  6. Lilly USA, LLC $528 22 payments
  7. Incyte Corporation $527 13 payments
  8. Novartis Pharmaceuticals Corporation $432 21 payments
  9. Regeneron Healthcare Solutions, Inc. $404 9 payments
  10. Pfizer Inc. $361 18 payments
  11. Other $2,025 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,006 28 payments
  2. Food and Beverage $10,166 386 payments
  3. Travel and Lodging $4,633 37 payments
  4. Consulting Fee $1,400 2 payments
  5. Education $816 12 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $56,911 93 payments
  2. Cimzia $3,715 12 payments
  3. TREMFYA $1,146 43 payments
  4. DUPIXENT $796 32 payments
  5. SKYRIZI $540 32 payments
  6. OPZELURA $527 13 payments
  7. ILUMYA $495 24 payments
  8. CIBINQO $345 17 payments
  9. TALTZ $312 16 payments
  10. RINVOQ $288 11 payments
  11. Other $4,583 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

488

Median for Nurse Practitioner: 389

Drug cost

$14,295

Median for Nurse Practitioner: $21,885

Branded share of claims

6.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 51 $3,229
Tacrolimus Generic 23 $2,032
Fluorouracil Generic 18 $1,730
Ketoconazole Generic 72 $1,371
Doxycycline Hyclate Generic 40 $1,243
Metronidazole Generic 21 $1,176
Fluocinonide Generic 24 $1,010
Triamcinolone Acetonide Generic 93 $749
Doxycycline Monohydrate Generic 21 $453
Valacyclovir Valacyclovir Hcl Brand 19 $390

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$89,967

Of which drugs: $1,834

Medicare patients

651

Average age 75

Services billed

2,912

404 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 41%
Chronic kidney disease 19%
Osteoporosis 19%
Diabetes 17%
Depression 17%
Ischemic heart disease 15%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 41 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $18,942
$18,942 — —
TREMFYA
  • Janssen Biotech, Inc. $189
$189 — —
OPZELURA
  • Incyte Corporation $188
$188 — —
DUPIXENT
  • GENZYME CORPORATION $96
  • Regeneron Healthcare Solutions, Inc. $41
$138 — —
SKYRIZI
  • AbbVie, Inc. $137
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

465 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record